Evidence map›Paper›PMID 33865425›Full record

ArticleChinese medicine2021

In vitro anti-bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection.

Xue Shen, Weijia Zhang, Chang Peng, Jiahui Yan, Pengting Chen, Cheng Jiang, Yuemei Yuan, Donglian Chen, Weixing Zhu, Meicun Yao

Abstract read
In one paragraph

Article in Chinese medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Harnessing network pharmacology in drug discovery: an integrated approach.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Antimicrobial Effects ofDrug design, development and therapy · 2025
    Article
  7. Frontiers in microbiology · 2025
    Article
  8. Helile formula from "Tai ping sheng hui fangFrontiers in cellular and infection microbiology · 2025
    Article
  9. Article
  10. 1,3,6-Trigalloylglucose: A Novel Potent Anti-Molecules (Basel, Switzerland) · 2024
    Article
  11. Frontiers in microbiology · 2024
    Article
  12. Chebulinic acid isolated from aqueous extracts ofFrontiers in microbiology · 2024
    Article
  13. Preliminary investigation of theFrontiers in pharmacology · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Asclepain cI, a proteolytic enzyme fromFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xue ShenSchool of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, 510006, China.
Weijia ZhangSchool of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, 510006, China.
Chang PengSchool of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Guangzhou, 510006, China.
Jiahui YanSchool of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, 510006, China.
Pengting ChenSchool of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, 510006, China.
Cheng JiangSchool of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Guangzhou, 510006, China.
Yuemei YuanSchool of Ecology, Sun Yat-Sen University, Guangzhou, 510006, China.
Donglian ChenQingyuan Hospital of Traditional Chinese Medicine, Qingyuan, 511500, China.
Weixing ZhuQingyuan Hospital of Traditional Chinese Medicine, Qingyuan, 511500, China. zhuweixingys@163.com.
Meicun YaoSchool of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Guangzhou, 510006, China. lssymc@mail.sysu.edu.cn.

Funding

National Natural Science Foundation of China 81973552
6 · The paper itself

Abstract

backgroundHelicobacter pylori (H. pylori) infection has become an international public health problem, and antibiotic-based triple or quadruple therapy is currently the mainstay of treatment. However, the effectiveness of these therapies decreases due to resistance to multiple commonly used antibiotics. Sanguisorba officinalis L. (S. officinalis), a traditional Chinese medicine clinically used for hemostasis and treatment of diarrhea, has various pharmacological activities. In this study, in vitro antimicrobial activity was used for the preliminary evaluation of S. officinalis against H. pylori. And a pharmacology analysis approach was also utilized to elucidate its underlying mechanisms against H. pylori infection.

methodsMicro-broth dilution method, agar dilution method, checkerboard assay, scanning electron microscopy (SEM), and transmission electron microscopy (TEM) were used for the assessment of anti-bacterial activity. Active ingredients screening, GO analysis, KEGG analysis, construction of PPI network, molecular docking, and RT-qPCR were used to elucidate the underlying pharmacological mechanisms of S. officinalis against H. pylori infection.

resultsThe minimum inhibitory concentration (MIC) values of S. officinalis against multiple H. pylori strains including clinically isolated multi-drug resistant (MDR) strains were ranging from 160 to 320 µg/ml. These results showed that S. officinalis had additive interaction with four commonly used antibiotics and could exert antibacterial effect by changing the morphology of bacteria without developing drug resistance. Through network pharmacology analysis, 8 active ingredients in S. officinalis were screened out for subsequent studies. Among 222 putative targets of S. officinalis, 49 targets were identified as potential targets for treatment of H. pylori infection. And these 49 targets were significantly enriched in GO processes such as protein kinase B signaling, protein kinase activity, protein kinase binding, and KEGG pathways such as Pathways in cancer, MicroRNAs in cancer, and TNF signaling pathway. Protein-protein interaction analysis yielded 5 core targets (AKT1, VEGFA, EGFR, SRC, CCND1), which were validated by molecular docking and RT-qPCR.

conclusionsOverall, this study confirmed the in vitro inhibitory activity of S. officinalis against H. pylori and explored the possible pharmacological mechanisms, laying the foundation for further research and clinical application.

Indexed as

Active ingredientsAntibacterialHelicobacter pyloriNetwork pharmacologySanguisorba officinalis L.

Identifiers

PMID33865425
PMCPMC8052767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.